Ideaya Biosciences (IDYA) announced a research collaboration with Attmos as part of its efforts to build a physics-based computational small molecule discovery platform that unlocks what are currently perceived as undruggable oncology targets. The collaboration will integrate Ideaya’s differentiated and proven capabilities in structural biology and pharmaceutical drug discovery across multiple oncology targets with Attmos’ capabilities in computational chemistry method development, high performance computing, and software development. The focus of the partnership will be to engineer and optimize a workflow solution for high-throughput absolute binding free energy perturbation predictions of drug candidate molecules.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Cautious Hold Rating on IDEAYA Biosciences Amid Anticipated Equity Raises and Financial Pressures
- IDEAYA Biosciences Reports 2024 Financials and Business Update
- IDEAYA Biosciences: Strategic Advancements and Promising Clinical Developments Support Buy Rating
- Strategic Advancements and Clinical Progress Drive IDEAYA Biosciences’ Buy Rating
- Ideaya Biosciences price target lowered to $40 from $53 at Oppenheimer
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue